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Background: The Liu Comorbidity Index uses the United States Renal Data System (USRDS) to quantify comorbidity
in chronic dialysis patients, capturing baseline comorbidities from days 91 through 270 after dialysis initiation. The
270 day survival requirement results in sample size reductions and potential survivor bias. An earlier and shorter
time-frame for data capture could be beneficial, if sufficiently similar comorbidity information could be ascertained.
Methods: USRDS data were used in a retrospective observational study of 70,114 Medicare- and Medicaid-eligible
persons who initiated chronic dialysis during the years 2000–2005. The Liu index was modified by changing the
baseline comorbidity capture period to days 1–90 after dialysis initiation for persons continuously enrolled in
Medicare. The scores resulting from the original and the modified comorbidity indices were compared, and the
impact on sample size was calculated.
Results: The original Liu comorbidity index could be calculated for 75% of the sample, but the remaining 25% did
not survive to 270 days. Among 52,937 individuals for whom both scores could be calculated, the mean scores for
the original and the modified index were 7.4 ± 4.0 and 6.4 ± 3.6 points, respectively, on a 24-point scale. The most
commonly calculated difference between scores was zero, occurring in 44% of patients. Greater comorbidity was
found in those who died before 270 days.
Conclusions: A modified version of the Liu comorbidity index captures the majority of comorbidity in persons who
are Medicare-enrolled at the time of chronic dialysis initiation. This modification reduces sample size losses and
facilitates inclusion of a sicker portion of the population in whom early mortality is common.
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Studies using large, observational data sets are vitally
important sources of evidence for clinical populations in
which randomized trials are difficult to conduct [1-3].
Persons with advanced renal disease are excluded from
most randomized, clinical trials (RCT) of treatments for
other disease states [4-8]. Even when feasible, RCT re-
sults may not generalize well to broader clinical popula-
tions because only the most select subset of persons can* Correspondence: srigler@kumc.edu
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reproduction in any medium, provided the orbe enrolled and randomized. Observational studies im-
prove generalizability but are fraught with treatment se-
lection bias [9]. Valid measures of comorbid disease
burden and mortality risk must therefore be incorpo-
rated to adjust for non-random treatment selection in
real-world care [10,11].
Chronic dialysis patients have higher rates of cardiovas-
cular comorbidity and reduced survival in comparison to
the general population from which most comorbidity in-
dices are derived [12,13]. Thus, comorbidity measures
designed specifically for the chronic dialysis population
may be preferable [14,15]. The United States Renal Data
System (USRDS) is an important source of observational
data for studies of the chronic dialysis population [16]. The
USRDS incorporates demographic information, Medicaretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to be captured), and baseline health status information
from the CMS Medical Evidence Form (CMS 2728) which
is completed at the time of dialysis initiation.
In 2010, Liu et al. created a new comorbidity index using
USRDS data as a basis [17]. Because new chronic dialysis
initiates may take up to 90 days to acquire Medicare eligi-
bility, claims data were frequently found to be missing
during the first 90 days after dialysis initiation. Thus, these
investigators set the start-date for capturing Medicare
claims-based diagnoses at day 91. A subsequent six month
period for comorbidity capture was used, spanning days
91 to 270 after dialysis initiation. Outcomes were then
evaluated from day 271 onward. This index performed
better than the traditional Charlson Comorbidity Index
(CCI) and was predictive of mortality, hospitalization and
medical costs [17].
The current study is prompted by concerns about the
time period required to acquire claims-based diagnoses
codes for calculation of the original Liu comorbidity
score. If the original Liu index can only be applied to pa-
tients who survive at least 270 days after starting dialy-
sis, then it limits the study sample to a healthier subset
of dialysis initiates. Because more than one in five pa-
tients starting dialysis will not survive their first year
[17], such a survival requirement will reduce sample size
and lessen the generalizability of study results because
sicker patients are excluded from study [18]. The alter-
native is for investigators to apply other comorbidity in-
dices which were not developed specifically for this
unique population, and neither option is ideal.
To meet study purposes for our own USRDS-based pro-
jects, our research sample includes only persons who are
already Medicare-eligible at the time of dialysis initiation.
Because Medicare claims data are thus available in the first
90 days for all subjects, we explored the option of com-
mencing the capture of baseline comorbidity immediately
upon dialysis initiation. In addition, we reasoned that a
shorter time period for baseline comorbidity ascertain-
ment would also help reduce sample size losses and im-
prove generalizability, while allowing the post-baseline
outcomes assessment period to begin sooner. However,
we recognized that a shorter baseline period for observing
Medicare claims-based diagnoses might impede total co-
morbidity ascertainment. The results of “trading off” time
in the baseline period (where baseline comorbidities are
captured) for time in the post-baseline period (where out-
comes are captured) have not been studied with this index.
In chronic dialysis, where median survival is less than
three years after dialysis initiation, this is a pressing design
issue for observational studies [16,17].
Thus, our goals were to examine the impact of modifying
the Liu Comorbidity Index by: (a) shifting the start date for
comorbidity capture forward to begin immediately afterdialysis initiation (Day 0), and (b) shortening the total
baseline period for comorbidity capture from 180 days to
90 days. We applied these changes to a population with
Medicare coverage in place at the time of dialysis initi-
ation. We characterized the impact on sample size and
compared the comorbidity scores resulting from the ori-
ginal index and the new modification.
Methods
Sample
This study arose from a larger project in which USRDS
data was linked to Medicaid pharmacy claims for the
period 1/1/2000-12/31/2005. All subjects were dually-
eligible for both Medicare and Medicaid from the time
of dialysis initiation and throughout subsequent observa-
tion. Subjects with managed care plans and those receiv-
ing care in the Veterans Affairs system were excluded
because their health care claims could not be observed.
Other pragmatic data limitations required exclusion of
residents of Arizona, Tennessee and the United State
Territories. Persons who moved from one state to an-
other during observation were also excluded.
All subjects had to survive the first 90 days or more
after dialysis initiation without receiving kidney trans-
plantation. From this larger pool of chronic dialysis pa-
tients, an incident cohort of persons initiating dialysis
was selected. The derivation of this incident cohort has
been previously reported elsewhere [19].
Variables
The CMS 2728 form provided data from the time of dia-
lysis initiation, including sociodemographic factors (age,
gender, race/ethnicity, employment, tobacco use, sub-
stance abuse), general health status factors (inability to
ambulate, inability to transfer, body mass index), and
renal health factors (primary cause of end stage renal
disease, in-center versus home dialysis, hemoglobin
adequacy indicator). Selected comorbid disease (e.g., dia-
betes mellitus, heart failure, coronary artery disease,
cerebrovascular disease, peripheral vascular disease) also
came from the CMS 2728 form. The remaining condi-
tions of interest were captured from Medicare claims
using standard methods for inferring the presence of dis-
ease from service claims linked to ICD-9-CM codes for
these conditions [17].
As per the original Liu index, diagnoses were consid-
ered present if they were found on either the CMS 2728
or in Medicare claims.
Two versions of the Liu Comorbidity Index
We first calculated the original Liu Comorbidity Index,
gathering Medicare claims-based diagnoses from days 91
to 270 after dialysis initiation to supplement conditions
recorded on the CMS 2728. Briefly, this index assigns 11
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otic heart disease and for diabetes; 2 points for cerebro-
vascular accident/transient ischemic attack, peripheral
vascular disease, dysrhythmia, other cardiac disease,
chronic obstructive pulmonary disease, gastrointestinal
bleeding, liver disease and cancer; and 3 points for con-
gestive heart failure. We used the version of the original
Liu index which also assigns points for the primary
cause of ESRD, as follows: glomerulonephritis (0 point),
hypertension (2 points), diabetes (3 points), and other
causes (3 points). In this form, the Liu Comorbidity
Index results in a score ranging from 0 to 24 points [17].
Next, we modified the original Liu index. We retained
the same variables and scoring weights but with two
modifications to the time-frame of baseline comorbidity
capture. First, we allowed claims-based diagnoses cap-
ture to commence immediately upon dialysis initiation,
instead of forcing a 90-day waiting period. Second, we
reduced the total baseline claims capture period from a
180 day total span (days 91–270 in the original version)
to a 90 day span (days 1–90 in the modified version).
This newly modified comorbidity index is henceforth
called the Modified Liu Index 1–90, to indicate the days
in which claims are captured.
Analysis
Demographic and clinical characteristics were derived
for the overall cohort and for the relevant comorbidity
index subgroups, as follows. We calculated the propor-
tion of our overall cohort who survived long enough to
be eligible to have been included in both comorbidity in-
dices; i.e., at least 270 days of survival after dialysis initi-
ation for the original Liu Index and at least 90 days for
the Modified Liu Index 1–90. We calculated the Modified
Liu Index 1–90 for all subjects, and we also calculated the
original Liu Index on the sample subgroup who would
have been eligible for both. The numeric score difference
between these two indices was calculated for each sub-
ject who had both measures calculated. Descriptive sta-
tistics were obtained for the score differences. Bubble
plots were examined to assess overlap between the two
measures and the Pearson correlation coefficient was es-
timated, along with 95% confidence intervals. To further
evaluate the Modified Liu Index 1–90 as an estimate of
the original Liu Index, we conducted a one-sample t-test
of the score difference to test for bias (indicated if the
average difference between the two measures was not
zero) in this estimate and calculated the mean square
error (MSE) [20]. The MSE was estimated by the sum of
the sample variance for the original Liu Index and the
square of the bias. The proportions of subjects whose
differences were zero, within one, two, three, four, and
five were estimated along with their corresponding 95%
Wald confidence intervals. A histogram of the scoredifferences was also generated with a normal distribu-
tion overlaid.
To evaluate differences in demographic and clinical
characteristics between those for whom both comorbid-
ity measures were calculated (i.e., those that survived at
least 270 days on dialysis) versus those that survived at
least 90 days (but less than 270 days), bivariate analyses
were conducted. This included contingency tables and
the Pearson chi-square test for categorical measures, and
means, standard deviations, and the two-sample t-test
for continuous measures.
SAS version 9.2 (SAS Institute, Inc., 2002–2008) was
used for data management and analysis. This study was
approved by the University of Kansas Medical Center’s
Human Subjects Committee. Data were used under data
use agreements with the USRDS and the Centers for
Medicare & Medicaid Services.Results
There were 70,114 subjects with complete data. The
original Liu Index could be calculated for 75% of these
(n = 52,937), while the remaining 25% (n = 70,114-52,937)
did not survive long enough to meet the requirements for
calculation of the original Liu Index. Table 1 shows the
demographic and clinical characteristics of the overall co-
hort and these two subgroups.
For subjects who survived long enough to have both
versions of the index calculated, good overlap between
the two comorbidity scores was observed using bubble
plots (not shown); the Pearson correlation coefficient
was 0.74 (95% confidence interval: 0.73-0.74). The me-
dian and mode for the difference between the comorbid-
ity scores were both equal to zero. See Figure 1. Mean
scores ± standard deviation for the original index and
the modified index were 7.4 ± 4.0 and 6.4 ± 3.6 points,
respectively, generating a difference (estimated bias) of
0.98 ± 2.8 points (p < 0.0001 for test of no bias). The
MSE for the Modified Liu Index 1–90 as an estimator of
the original Liu Index was approximately 16.87, making
the root MSE 4.1. The two scores were exactly equal for
43.9% (95% confidence interval: 43.5-44.3%) of individ-
uals. The proportions with differences within one to five
points were (respectively) 51.4%, 71.6%, 79.7%, 87.3%,
and 92.1%, with each having narrow confidence inter-
vals similar to that for those whose scores were exactly
equal.
For the 25% of subjects who lived at least 90 days but
less than 270 days, the mean Modified Liu Index 1–90
score was 7.3 ± 4.2 points. This group differed in health
status from those who survived the 270 days on most
variables, as shown in Table 1, but the differences be-
tween groups were generally not more than a few per-
centage points.
Table 1 Demographic & clinical characteristics of study sample
Variable Total cohort
(n = 70,114)
Survived < 270 days
(n = 17,177)
Survived ≥ 270 days
(n = 52,937)
± p-value
Comorbidity index scores
*Original Liu Comorbidity Index Score
(mean ± st. dev.)
Cannot be
calculated
Cannot be calculated 7.35 ± 3.99 N/A
**Modified Liu Comorbidity Index Score
(mean ± st. dev.)
6.60 ± 3.75 7.30 ± 4.16 6.37 ± 3.58 <0.0001
Demographic and clinical characteristics
Age (years) (mean ± st. dev.) 61.5 ± 15.4 62.3 ± 16.4 61.2 ± 15.1 <0.0001
Gender (% women) 56.2% 53.8% 57.0% <0.0001
Race/Ethnicity <0.0001
Black 40.3% 39.0% 40.8%
Hispanic 18.0% 15.8% 18.8%
Other 6.0% 5.2% 6.2%
White 35.7% 40.0% 34.3%
Employed 2.5% 3.2% 2.3% <0.0001
Tobacco use 6.4% 6.4% 6.4% 0.7830
Substance abuse 2.9% 2.9% 2.8% 0.7413
Unable to ambulate 5.8% 7.9% 5.2% <0.0001
Unable to transfer 2.1% 3.3% 1.8% <0.0001
Home dialysis 4.9% 4.6% 5.0% 0.0589
Body Mass Index <0.0001
<20 10.4% 12.5% 9.7%
≥20 to < 24.99 30.0% 31.5% 29.5%
≥25 to <29.99 26.9% 26.2% 27.1%
≥30 32.8% 29.9% 33.7%
Hemoglobin >11 mg/dL 25.0% 24.8% 25.0% 0.4501
Primary renal diagnosis: <0.0001
Diabetes mellitus 53.0% 49.3% 54.2%
Hypertension 25.7% 26.5% 25.4%
Immune 7.4% 7.5% 7.3%
Other 14.0% 16.8% 13.1%
¶Diabetes mellitus 62.8% 60.3% 63.7% <0.0001
Congestive heart failure 34.2% 37.1% 33.3% <0.0001
Coronary artery disease 25.4% 27.2% 24.8% <0.0001
Cerebrovascular disease 11.1% 12.5% 10.6% <0.0001
Peripheral vascular disease 14.8% 16.6% 14.3% <0.001
*Original Liu Index captures comorbidity data from days 91–270 after dialysis initiation.
** Modified Liu Index 1–90 captures comorbidity data from days 1–90 after dialysis initiation.
± p-value for bivariate test statistic by survival group.
¶ Diabetes considered present if either noted as the primary cause for renal failure or as a comorbidity in claims data.
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Our goals were to determine the impact of a modified
data capture period on Liu Comorbidity Index values for
a large sample of incident chronic dialysis patients in
whom Medicare coverage was already in place at the
time of dialysis initiation. We found that approximately
32% more subjects could be retained if the comorbiditycapture period was modified to require survival to only
the first 90 days after dialysis initiation. These shorter
survivors were, as expected, somewhat sicker on average
than those who survived into the 91–270 day capture
period (or longer), as evidenced by a slightly higher co-
morbidity score (approximately one point higher on a 24
point scale).
Figure 1 Distribution of difference between original and
modified Liu index scores.
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ity capture were to enhance the study size and to expand
the breadth of baseline health status in the subject pool.
For study design purposes, this shorter baseline health
ascertainment period also has the beneficial impact of
allowing for a longer period of post-baseline follow-up
observation in which subjects experience the health out-
comes of interest. This may be an especially attractive
feature for observational studies populations with short-
ened survival, such as is the case with chronic dialysis
patients.
Conversely we were concerned that the shorter period
of claims-based comorbidity ascertainment could result
in reduced ascertainment of overall comorbidity because
fewer health care claims would be generated during the
shorter observation period. A modest difference was
indeed noted, but it averaged only a single point on a
24-point scale. Indeed, the most common change in co-
morbidity score was no change at all, present in nearly
half the individuals. For other investigators, we would
suggest that this modest reduction in ascertainment of
comorbidity (which is typically used as one of many
adjustment covariates) is a price well worth paying in
order to prevent a one-third sample size loss and the
elimination of the sickest patients from a study cohort.
Existing comorbidity measures
The Liu index is important because (a) it was developed
specifically for use in the chronic dialysis population;
and (b) it relies only upon diagnoses derived from the
CMS 2728 form and/or Medicare claims. No additional
clinical measures are needed, making it practical for ap-
plication to a host of observational claims-based studies
in the USRDS. However, it must be noted that other in-
vestigators have used pre-existing comorbidity tools to
successfully characterize the impact of comorbidity onoutcomes in chronic dialysis populations. Published lit-
erature generally supports the validity of these general
comorbidity measures in this population, despite the fact
that they were developed in dissimilar clinical
populations.
However, most of these studies have relied upon first-
hand clinical data rather than administrative claims, so
their applicability to administrative claims-based studies
is unclear. Hemmelgarn et al. adapted the Charlson co-
morbidity index [21] for use in chronic dialysis patients,
finding only a slight advantage for the modified version
[22]. However, comorbid diagnoses were abstracted from
clinical chart data. The studies of van Manen et al.
showed three existing comorbidity indices (Khan, Davies
and Charlson) to be appropriate for characterizing the im-
pact of comorbidity on mortality [23] and on health status
and quality of life in chronic dialysis patients [24]. How-
ever, in this case, data on the presence and severity of co-
morbid diagnoses came from each patient’s nephrologist.
Other investigators have developed tools specifically for
the chronic dialysis population but which require data
sources that are not available in claims. Miskulin et al.
used the Index of Coexistent Disease to characterize co-
morbid disease burden at the time of dialysis initiation
and thereafter, finding that the baseline ICED score was
the best independent predictor of mortality during subse-
quent follow-up [25]. However, along with disease severity
indicators, this index also incorporates physical impair-
ment information that is not available from the USRDS.
Limitations
Study limitations must be noted. First, this study sample
was comprised only of persons who were dually eligible
for both Medicare and Medicaid; results may not be
generalizable to other chronic dialysis patients [26]. Sec-
ond, these results apply only to persons who are already
Medicare eligible at the time of dialysis initiation. How-
ever, this is a large subset of the chronic dialysis popula-
tion; 58% of new hemodialysis patients have non-managed
care Medicare coverage [16]. Third, as with any claims-
based comorbidity index, diseases are ascertained only if
there are coded health care service claims available in the
administrative data sets; these data were not confirmed
with direct evidence from medical records. However, such
approaches are standard and necessary when working with
large administrative data sets [27].
Conclusions
In conclusion, we found that a simple modification of
the original Liu comorbidity index provided reasonably
comparable comorbidity ascertainment and allowed re-
tention of a sizable and particularly vulnerable portion
of chronic dialysis initiates. The benefits of this approach
are a larger sample size, reduced healthier-survivor bias
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survival time available for outcome assessment. We con-
clude that nephrology health services researchers should
consider using this modification for comorbidity adjust-
ment if they are conducting observational studies with
similar data sets and insurance eligibility requirements.
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